Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 6:26 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 4,268 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: ADM Clear all

Conditions: Infertility, Female
Interventions: sonoHSG; Procedure
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Manhasset, New York

Conditions: Breast Cancer, Estrogen Receptor-positive Breast Cancer
Interventions: Aspirin, Tamoxifen Pill, Doxorubicin, Cyclophosphamide, Paclitaxel; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Vascular Access Complication
Interventions: AccuCath IV Catheter Device, Conventional IV Catheter Device; Device
Lead sponsor: C. R. Bard; Industry
Eligibility: 18 Years to 89 Years
Enrollment: 248 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Cesarean Section, Delivery; Trauma
Interventions: General anesthetic, Intravenous anesthetic; Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older · Female only
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Intraoperative Awareness, General Anesthesia
Interventions: Not listed
Lead sponsor: University of Chicago; Other
Eligibility: 7 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Tobacco Use Disorder, HIV
Interventions: PSFW+, AHA, Nicotine polacrilex; Behavioral · Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 512 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 2
States / cities: Baltimore, Maryland • The Bronx, New York

Conditions: Lymphoma, Follicular
Interventions: Ofatumumab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone, Prednisone or equivalent; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Breast Cancer
Interventions: Myocet; Drug
Lead sponsor: Sopherion Therapeutics; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 363 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 18
States / cities: San Diego, California • Aurora, Colorado • Coral Springs, Florida + 15 more

Conditions: Lymphoma, Hodgkin Disease, Lymphoma, Hodgkin Disease, Lymphoma: Hodgkin
Interventions: Vincristine, Cyclophosphamide, Doxorubicin, Prednisone, Bleomycin, Etoposide, Low-dose radiotherapy (RT); Drug · Radiation
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2017
U.S. locations: 2
States / cities: Stanford, California • Vallejo, California

Conditions: Osteoarthritis, Hip
Interventions: Femoral Component:Medacta Masterloc Stem and Medacta MPACT cup.; Device
Lead sponsor: Medacta USA; Industry
Eligibility: Up to 75 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2024
U.S. locations: 3
States / cities: Oro Valley, Arizona • West Jordan, Utah • Spokane, Washington

Conditions: Insomnia, Hypnotic Dependence
Interventions: Digital Cognitive Behavioral Therapy, Structured Medication Tapering; Behavioral
Lead sponsor: National Jewish Health; Other
Eligibility: 21 Years and older
Enrollment: 430 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Diet Modification, Lung Cancer
Interventions: Special Diet Therapy (low-carb), Special Diet Therapy (low-fat), Special Diet Therapy (USDA control); Behavioral
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Bone Marrow Transplant
Interventions: Online Yoga, Podcast; Behavioral
Lead sponsor: Arizona State University; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Chronic Pain
Interventions: Pain Catastrophizing Class, Health Education; Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 213 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Drug Abuse
Interventions: Computer-delivered Brief Intervention (CBI), Intervener-delivered Brief Intervention (IBI), Adapted Motivational Enhancement Therapy (AMET), Enhanced Usual Care (EUC); Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 60 Years
Enrollment: 878 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Flint, Michigan

Conditions: Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma, High Grade B-Cell Lymphoma
Interventions: Bone Marrow Biopsy, Cyclophosphamide, Doxorubicin, Prednisone, Retifanlimab, Rituximab and Hyaluronidase Human, Tafasitamab, Vincristine, Bone Marrow Aspiration, Multigated Acquisition Scan, Fludeoxyglucose F-18, Positron Emission Tomography, Computed Tomography, Biospecimen Collection, Polatuzumab Vedotin; Procedure · Drug · Biological + 1 more
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Hospitalism in Children
Interventions: Pediatric hospitalist program, General Pediatric Inpatient Services; Other
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: Up to 18 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Osteoarthritis, Knee
Interventions: Off-the-Shelf Implant Total Knee Replacement, Customized Implant Total Knee Replacement; Device
Lead sponsor: Restor3D; Industry
Eligibility: 18 Years and older
Enrollment: 59 participants
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Kettering, Ohio

Conditions: Stage I Mantle Cell Lymphoma, Stage II Contiguous Mantle Cell Lymphoma, Stage II Non-Contiguous Mantle Cell Lymphoma, Stage III Mantle Cell Lymphoma, Stage IV Mantle Cell Lymphoma
Interventions: Autologous Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Methotrexate, Ofatumumab, Vincristine Sulfate; Procedure · Drug · Other + 1 more
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years to 70 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2024
U.S. locations: 2
States / cities: Buffalo, New York • Nashville, Tennessee

Conditions: Lymphoma
Interventions: pegfilgrastim, rituximab, cyclophosphamide, doxorubicin hydrochloride, lenalidomide, prednisone, vincristine sulfate, polymorphism analysis, laboratory biomarker analysis; Biological · Drug · Genetic + 1 more
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 120 Years
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2024
U.S. locations: 3
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: T Acute Lymphoblastic Leukemia, T Lymphoblastic Lymphoma
Interventions: Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Mercaptopurine, Methotrexate, Nelarabine, Pegaspargase, Prednisone, Venetoclax, Vincristine Sulfate; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Ovarian Neoplasms
Interventions: Telcyta, Liposomal Doxorubicin; Drug
Lead sponsor: Telik; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 244 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 63
States / cities: Casa Grande, Arizona • Little Rock, Arkansas • Antioch, California + 49 more

Conditions: Glioblastoma, IDH-wildtype, Glioblastoma, Glioblastoma Multiforme of Brain, Astrocytoma, Malignant, Brain Neoplasms, Brain Neoplasms, Adult, Malignant, Brain Neoplasms, Adult, Recurrent Adult Brain Tumor, Recurrent Glioblastoma
Interventions: Awake mapping under local anesthesia, Asleep mapping under general anesthesia, Resection under general anesthesia without mapping; Procedure
Lead sponsor: Erasmus Medical Center; Other
Eligibility: Up to 90 Years
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 2
States / cities: San Francisco, California • Boston, Massachusetts

Conditions: Transmission, Blood, Recipient/Donor
Interventions: Not listed
Lead sponsor: Haemonetics Corporation; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 161 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Denver, Colorado

Search by objective public record fields.

Safety and Efficacy of Sonohysterosalpingography for the Evaluation of Infertility

COX Inhibition and Biomarkers During Neoadjuvant Chemoendocrine Therapy for ER+, HER2- Stage I-III Breast Cancer

AccuCath Guidewire Intravenous (IV) Device Versus Conventional IV Catheter In General Nursing Use

Early General Anesthesia to Limit Experiences of Trauma During Cesarean Section-Pilot Study

Study to Determine if Patients Exposed to General Anesthesia Significant Numbers of Times Would Increase the Risk for Intraoperative Awareness.

RCT of an Internet Cessation Program Plus Online Social Network for HIV+ Smokers

Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide,Doxorubicin, Vincristine, Predisolone) in Follicular Lymphoma (FL) Patients

Trial of Myocet in Metastatic Breast Cancer

Combination Chemotherapy Plus Low-Dose Radiation Therapy in Treating Patients With Stage I or Stage IIA Hodgkin's Lymphoma

Analysis of a Tapered Porous Coated Stem and a Cementless Hemispherical Acetabular Component

Enhancing Hypnotic Medication Discontinuation in Primary Care

Reducing Insulin, Growth Hormones, and Tumors

BMT Online Wellness Study

Single Session Class to Reduce Opioid Use in Chronic Pain

Healthier You: Optimizing Screening, Brief Interventions, and Referral to Treatment (SBIRT) in the Emergency Department

Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma

Benefits and Cost-Effectiveness of a Pediatric Hospitalist Service : a Stepped Wedge Quality Improvement Trial

TKA Operating Room Efficiency for TKA Using Customized Implant Techniques

Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

Lenalidomide, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large Cell or Follicular B-Cell Lymphoma

Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Phase 3 Randomized Study of Telcyta + Doxorubicin Versus Doxorubicin in Platinum Refractory or Resistant Ovarian Cancer

The RECMAP-study: Resection With or Without Intraoperative Mapping for Recurrent Glioblastoma

Procedure For The Reference Range Study For Absolute MA